Nasdaq GlobeNewswire

London Court of Appeal Validates IPCom's Mobile Telecoms Patent Critical to the UMTS Standard

Del

IPCom GmBH & Co. KG / London Court of Appeal Validates IPCom's Mobile Telecoms Patent Critical to the UMTS Standard . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Mobile Telecoms Patent is essential to UMTS networks

MUNICH, Germany, Jan. 09, 2018 (GLOBE NEWSWIRE) -- IPCom, a leading patent licensing entity with a global portfolio of mobile telecommunications patents, today announced that, earlier in 2017, the London Court of Appeal confirmed both the validity and infringement of IPCom's mobile telecoms European Patent (EP 1 841 268) (the "'100A") in its decision against the leading global handset vendor, HTC. The confirmation by the Court of Appeal of the validity of this critical patent and of HTC's infringement demonstrates the value and quality of this technology to mobile telecommunications companies.  In the event that the parties are unable to reach a settlement on the terms of a fair, reasonable and non-discriminatory ("FRAND") license, the parties will move next to the damages inquiry phase of the action.  In addition to the 100A action in the United Kingdom, as part of its ongoing effort to protect its intellectual property rights, IPCom recently filed a lawsuit against HTC in Germany for infringement of two additional IPCom patents. 

"We're pleased the Court found, after significant investigation and appeals, that the 100A is valid and essential to the UMTS standard," said Bernhard Frohwitter, managing director and co-founder of IPCom. "At long last, this paves the way for the industry as a whole to move forward with clear direction established by the court system. IPCom, with a portfolio of over 1,150 relevant or essential patents, stands ready to engage diligently with all manufacturers and service providers in the mobile industry."

Achieving this confirmation of validity and infringement was long and hard-fought but the decision by the Court of Appeal establishes that the 100A is standard-essential and mandatory to the UMTS standard. This particular patent is related to controlling how UMTS mobile telephones gain initial access to the network. As a result, any entity developing networks, handsets, or equipment for today's mobile networks should be engaging with IPCom regarding this critical element, as well as the hundreds of other relevant mobile technology patents within the firm's portfolio.

IPCom continues to engage with any industry participants who wish to take licenses on FRAND conditions as set forth by the European Commission and relayed to the European Telecommunications Standards Institute (ETSI). IPCom has a policy of offering all market participants implementing standards-compliant products and services FRAND licences and has been diligently doing so for many years. The confirmation of the 100A's validity and infringement by implementation of the UMTS standard reinforces the fact that UMTS implementors, if not already licensed, should be taking steps to negotiate with IPCom concerning its essential patent portfolio.

Companies manufacturing or selling mobile devices or offering services compliant with 2G (GMS), 2.5G (GPRS), 3G (UMTS) and 4G (LTE) should, therefore, contact IPCom to request a FRAND license agreement.  To request a license, please send your company name and contact information to ross@ipcom-munich.com

About IPCom
IPCom is a Patent Licensing Entity founded in 2007 to establish a link between patent developers and patent users. Its core business is the global licensing of patents from its own portfolio to manufacturers in the industry. Bosch originally developed IPCom's patents. The current patent portfolio encompasses approximately 1150 patents in the field of mobile communications, registered in Europe, the US and Asia. Among these are a number of patents that are declared standard-essential for the key mobile communications standards of 2G (GMS), 2.5G (GPRS), 3G (UMTS) and 4G (LTE).

For more information: 
Jay Nichols
Nichols Communications
jay@nicholscomm.com
Tel: +1 408-772-1551 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: IPCom GmBH & Co. KG via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

CORRECTION - Elite Petro & Gas broadens financial services and signs a deal with Tabarak Investment Capital Limited18.10.2018 23:35Pressemelding

DUBAI, United Arab Emirates, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Today the President of Elite Petro & Gas, Mr. George Matharu and the President of Tabarak Investment Capital Limited (Investment Bank), Dr. Mohamed Ahmadi announced a deal in which the two companies will use their combined resources to execute physical commodity trades, and provide banking and finance facilities for oil and gas transactions. The alliance between the two entities will also allow compliance related activities to be carried out from two major international hubs of London and Dubai. This increases the international presence of both companies. Additionally, Elite Petro & Gas (“EPG”) has recently formed relationships with the owners of a number of high profile European, South American and Chinese projects, which EPG and Tabarak can work on together. Tabarak Investment Capital Limited is a regulated investment bank by Dubai Financial Services Authority and incorporated in the Dubai International Financial Centre.

Partnership Between Zaiput Flow Technologies and ThalesNano Set to Improve Process Intensification18.10.2018 15:21Pressemelding

BUDAPEST, Hungary and WALTHAM, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Zaiput Flow Technologies, a global leader in separation, and ThalesNano, the world leader in bench-top flow chemistry reactors, recently signed a distribution agreement and entered into a technology partnership that exploits the benefits of their combined technologies. Under the distribution Zaiput liquid-liquid phase separators and back pressure regulators are available via ThalesNano in Europe and a number of other countries on a non-exclusive basis, either separately or as part of a bundled offering with ThalesNano’s own microflow reactors. Within the framework of the technology partnership the companies will collaborate to promote adoption of the combined use of their technologies. “We are very excited to work with ThalesNano to offer better-integrated flow chemistry systems to our customers and streamline the work of both novice and experienced users in the flow chemistry space,” said Zaiput CEO, Dr. Andrea Ad

Abeona Therapeutics Appoints João Siffert, M.D. Head of Research and Development and Chief Medical Officer18.10.2018 14:03Pressemelding

NEW YORK and CLEVELAND, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the appointment of João Siffert, M.D. as Head of Research and Development and Chief Medical Officer. As a result, former Chief Medical Officer Juan Ruiz, M.D., Ph.D. will assume the role of Head of European Medical Affairs. The Company also announced the appointment of Neena Patil, J.D. as General Counsel and Corporate Secretary. Both Dr. Siffert and Ms. Patil report to Chief Executive Officer, Carsten Thiel, Ph.D. “I am very pleased to welcome João and Neena to Abeona, and confident in their abilities to make important contributions to the future growth of our company,” said Dr. Thiel. “João has an ideal blend of clinical, scientific, and regulatory experience to reference as we look to advance our clinical and pre-clinical can

Meltwater and Dow Jones Announce Global Partnership to Provide Premium Content18.10.2018 14:00Pressemelding

SAN FRANCISCO and NEW YORK, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Meltwater, a global leader in media intelligence, today announces the launch of a partnership with Dow Jones, a global provider of news and business information, to provide premium licensed content from Dow Jones Factiva into the Meltwater Media Intelligence platform. This partnership will give Meltwater’s PR and communications clients the ability to monitor and analyze premium licensed content across thousands of Factiva news sources globally, including: The Wall Street Journal, America’s largest newspaper by paid circulation; Barron’s; MarketWatch; and Dow Jones Newswires. “Meltwater provides our clients with the most comprehensive content network globally, across news, social media and broadcast media. This new Dow Jones partnership will further strengthen our leadership position and allow our clients to access licensed content from some of the most highly-respected news outlets in the world. We’re excited about this part

Biogen to Present Data from Alzheimer’s Disease Portfolio at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting18.10.2018 13:30Pressemelding

EMBARGOED FOR DISTRIBUTION Please note CTAD embargo policy: All materials submitted to CTAD are embargoed for publication and broadcast until the officially scheduled date and time of presentation, symposia or poster session. Data to be presented across the Alzheimer’s disease clinical development portfolio, including aducanumab, BAN2401 and elenbecestat CAMBRIDGE, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) announced it will present data from its Alzheimer’s disease (AD) clinical development portfolio at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) annual meeting in Barcelona, Spain (October 24-27). The data being presented are part of Biogen’s ongoing research programs targeting possible causes of the disease through multiple modalities. “We are excited to engage with the scientific community at CTAD, to share learnings from our Alzheimer’s disease clinical research and to learn from the work of our colleagues around the world. We have hopes that our

SEMAFO Provides Notice of Third Quarter 2018 Results Release and Conference Call   18.10.2018 13:30Pressemelding

MONTREAL, Oct. 18, 2018 (GLOBE NEWSWIRE) -- SEMAFO (TSX, OMX: SMF) invites you to participate in a conference call on November 7, 2018 at 10:00 AM EST with senior management during which they will review the Corporation's third quarter 2018 financial and operational results. SEMAFO's financial statements and management's discussion and analysis for the third quarter 2018 will be released on November 6 after market hours and will be available in the “Investor Relations” section of the Corporation's website at www.semafo.com , and on the Canadian Securities Administrators' website at www.sedar.com . A live audio webcast of the conference call will be accessible for a period of 30 days through SEMAFO’s website at www.semafo.com . Tel. local & overseas: +1 (647) 788 4922 Tel. North America: 1 (877) 223 4471 Webcast: www.semafo.com Replay overseas: +1 (416) 621 4642 Replay N. America: 1 (800) 585 8367 Replay pass code: 2823689 Expiration: December 7, 2018 About SEMAFO SEMAFO is a Canadian-b

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom